FGP
PTCT icon

Freestone Grove Partners’s PTC Therapeutics PTCT Stock Holding History

Freestone Grove Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$382K Sell
4,677
-10,823
-70% -$782K ﹤0.01% 711
2026
Q1 		$1.06M Buy
+15,500
New +$1.1M 0.01% 464

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Freestone Grove Partners's PTCT Position: Q2 2026 in Review

Freestone Grove Partners reduced its PTC Therapeutics (PTCT) stake by 70% in Q2 2026, selling an estimated $782K and leaving 4,677 shares worth $382K. The position accounts for ﹤0.01% of the portfolio, ranked #711.

Freestone Grove Partners first reported a position in PTCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.06M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Freestone Grove Partners held 4,677 shares of PTC Therapeutics worth $382K as of Q2 2026.
  • Freestone Grove Partners sold 10,823 PTC Therapeutics shares in Q2 2026, an estimated $782K.
  • PTC Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #711 holding.
  • Freestone Grove Partners first reported a position in PTC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Freestone Grove Partners's PTC Therapeutics position peaked at $1.06M in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.